Skip to Content
MilliporeSigma
  • Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis.

Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis.

Hepatology (Baltimore, Md.) (2014-02-13)
Ewa Wunsch, Jocelyn Trottier, Malgorzata Milkiewicz, Joanna Raszeja-Wyszomirska, Gideon M Hirschfield, Olivier Barbier, Piotr Milkiewicz
ABSTRACT

Ursodeoxycholic acid (UDCA) is no longer recommended for management of adult patients with primary sclerosing cholangitis (PSC). We undertook a prospective evaluation of UDCA withdrawal in a group of consecutive patients with PSC. Twenty six patients, all treated with UDCA (dose range: 10-15 mg/kg/day) were included. Paired blood samples for liver biochemistry, bile acids, and fibroblast growth factor 19 (FGF19) were collected before UDCA withdrawal and 3 months later. Liquid chromatography/tandem mass spectrometry was used for quantification of 29 plasma bile acid metabolites. Pruritus and health-related quality of life (HRQoL) were assessed with a 10-point numeric rating scale, the Medical Outcomes Study Short Form-36 (SF-36), and PBC-40 questionnaires. UDCA withdrawal resulted in a significant deterioration in liver biochemistry (increase of alkaline phosphatase of 75.6%; P<0.0001; gamma-glutamyl transpeptidase of 117.9%, P<0.0001; bilirubin of 50.0%, P<0.001; alanine aminotransferase of 63.9%, P<0.005; and aspartate aminotransferase of 45.0%, P<0.005) and increase of Mayo Risk Score for PSC (change from baseline of +0.5 point; P<0.003). Bile acid analysis revealed a significant decrease in lithocholic acid and its derivatives after UDCA withdrawal, but no effect on concentrations of primary bile acids aside from an increased accumulation of their taurine conjugates. After UDCA removal cholestatic parameters, taurine species of cholic acid and chenodeoxycholic acid correlated with serum FGF19 levels. No significant effect on HRQoL after UDCA withdrawal was observed; however, 42% of patients reported a deterioration in their pruritus. At 3 months, discontinuation of UDCA in patients with PSC causes significant deterioration in liver biochemistry and influences concentrations of bile acid metabolites. A proportion of patients report increased pruritus, but other short-term markers of quality of life are unaffected.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
3-Methyl-1-butanol, anhydrous, ≥99%
Sigma-Aldrich
Methanol, anhydrous, 99.8%
Supelco
Methanol, analytical standard
Sigma-Aldrich
Acetic acid, for luminescence, BioUltra, ≥99.5% (GC)
Sigma-Aldrich
Acetic acid, natural, ≥99.5%, FG
Sigma-Aldrich
Acetic acid, ≥99.5%, FCC, FG
Sigma-Aldrich
Methanol, suitable for HPLC, gradient grade, 99.93%
Sigma-Aldrich
Methanol, SAJ special grade
Sigma-Aldrich
Acetic acid, ≥99.7%
Sigma-Aldrich
Methanol, suitable for HPLC
Sigma-Aldrich
Acetic acid, 99.5-100.0%
Sigma-Aldrich
Acetic acid, SAJ first grade, ≥99.0%
Sigma-Aldrich
Methanol, SAJ first grade, ≥99.5%
Sigma-Aldrich
Acetic acid, JIS special grade, ≥99.7%
Sigma-Aldrich
Methanol, JIS 300, ≥99.8%, for residue analysis
Sigma-Aldrich
Acetic acid, ≥99.7%
Sigma-Aldrich
3-Methyl-1-butanol, JIS special grade, ≥98.0%
Sigma-Aldrich
3-Methyl-1-butanol, SAJ first grade, ≥96.0%
Sigma-Aldrich
Acetic acid, ≥99.7%, suitable for amino acid analysis
Sigma-Aldrich
Acetic acid solution, 1 M, 1 N
Sigma-Aldrich
Methanol, JIS special grade, ≥99.8%
Sigma-Aldrich
Methanol, NMR reference standard
Sigma-Aldrich
Acetic acid-12C2, 99.9 atom % 12C
Sigma-Aldrich
Methanol, HPLC Plus, ≥99.9%, poly-coated bottles
Supelco
Methanol, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
3-Methyl-1-butanol, analytical standard
Sigma-Aldrich
Methanol, Absolute - Acetone free
Sigma-Aldrich
3-Methyl-1-butanol, reagent grade, 98%
Sigma-Aldrich
Acetic acid, glacial, ACS reagent, ≥99.7%
Sigma-Aldrich
Methanol, ACS reagent, ≥99.8%